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Abstract
New Aspergillus species have recently been described with the use of multilocus sequencing in refractory cases of invasive aspergillosis.
The classical phenotypic identification methods routinely used in clinical laboratories failed to identify them adequately. Some of these
Aspergillus species have specific patterns of susceptibility to antifungal agents, and misidentification may lead to inappropriate therapy.
We developed a matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)-based strategy to ade-
quately identify Aspergillus species to the species level. A database including the reference spectra of 28 clinically relevant species from
seven Aspergillus sections (five common and 23 unusual species) was engineered. The profiles of young and mature colonies were analy-
sed for each reference strain, and species-specific spectral fingerprints were identified. The performance of the database was then
tested on 124 clinical and 16 environmental isolates previously characterized by partial sequencing of the b-tubulin and calmodulin
genes. One hundred and thirty-eight isolates of 140 (98.6%) were correctly identified. Two atypical isolates could not be identified, but
no isolate was misidentified (specificity: 100%). The database, including species-specific spectral fingerprints of young and mature colo-
nies of the reference strains, allowed identification regardless of the maturity of the clinical isolate. These results indicate that MALDI-
TOF MS is a powerful tool for rapid and accurate identification of both common and unusual species of Aspergillus. It can give better
results than morphological identification in clinical laboratories.
Keywords: Aspergillosis, Aspergillus, fingerprint, identification, MALDI-TOF mass spectrometry, species complex, spectra
Original Submission: 26 April 2010; Revised Submission: 27 June 2010; Accepted: 30 June 2010
Editor: G. Greub
Article published online: 29 July 2010
Clin Microbiol Infect 2011; 17: 750–755
10.1111/j.1469-0691.2010.03323.x
Corresponding author: M.-E. Bougnoux, Service de Microbiologie,
Hoˆpital Necker Enfants-Malades, 146 rue de Se`vres, 75015 Paris,
France
E-mail: marie-elisabeth.bougnoux@nck.aphp.fr
Introduction
Invasive aspergillosis (IA) remains a severe complication of
cytotoxic therapy. Despite the availability of new antifungal
agents, overall mortality rates range from 29% to 42% [1].
Until recently, it was largely admitted that only a small num-
ber of species of Aspergillus were responsible for IA, i.e.
Aspergillus fumigatus, the leading aetiological agent, Aspergillus
flavus, Aspergillus niger, Aspergillus terreus and Aspergillus nidu-
lans [2]. Several studies have reported cases of IA caused by
previously unrecognized Aspergillus species. These new, clini-
cally relevant species, have been identified with methods
based on multilocus sequencing (MLS) of genes coding for
b-tubulin, calmodulin or actin [3]. Currently, the genus
Aspergillus includes seven subgenera that are subdivided into
22 sections, each corresponding to a specific ‘species
complex’, grouping related species [4]. For instance, the sec-
tion Fumigati or ‘A. fumigatus complex’ includes not only
A. fumigatus, but also 34 other related species [5]. In clinical
settings, identification of aspergilli is routinely based on
determination of macroscopic and microscopic morpho-
logical characteristics, such as colour, shape, ornamentation,
and recognition of asexual or sexual stages [6]. These con-
ventional means of identification do not allow discrimination
between morphologically close species of Aspergillus (i.e.
species belonging to the same section), and many reports
have stressed the occurrence of misidentification with
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traditional phenotypic approaches [5,7–10]. Thus, the num-
ber of species responsible for IA has been underestimated.
Some of the newly described species responsible for IA
have decreased susceptibilities to multiple antifungal drugs
in vitro [8,10–13], and therapeutic failures have been
reported in cases of infection with Neosartorya fischeri [14],
Neosartorya pseudofischeri [15], Neosartorya hiratsukae [16],
Neosartorya udagawae [17], Aspergillus insuetus [18], Aspergillus
calidoustus [19] and Aspergillus niveus [20]. These species are
difficult to separate from more susceptible Aspergillus species,
sometimes from the same section, solely on the basis of
morphological criteria.
The choice of appropriate antifungal therapy is strongly
influenced by the inherent resistance phenotype of each
Aspergillus species, and correct identification is therefore of
paramount clinical importance [2,21]. Current recommenda-
tions include the use of molecular identification by MLS for
identification of individual species within the various Aspergil-
lus sections [3,22]. However, sequencing is time-consuming
and expensive for the identification of all isolates recovered
from clinical samples, stressing the need for rapid and accu-
rate new strategies for identification of these recently
described Aspergillus species.
Several studies have reported the efficiency of matrix-
assisted laser desorption ionization time-of-flight (MALDI-
TOF) mass spectrometry (MS) for fast and accurate identifi-
cation of bacterial, yeast and mould species [23–27]. How-
ever, this method has not been assessed for most of the
clinically relevant Aspergillus species. In our study, we
designed and validated a rapid identification method, using
MALDI-TOF-MS technology to discriminate clinically relevant
intra-section species of Aspergillus. We demonstrate that
MALDI-TOF MS technology is effective for accurate identifi-
cation of clinical isolates of Aspergillus recovered from
patients or from the environment.
Materials and Methods
Aspergillus strains
Twenty-eight reference strains, corresponding to 28 Aspergillus
species from seven sections, were chosen to represent the
vast majority of the species currently described as being
responsible for infection in humans. They included both com-
mon and unusual Aspergillus species, and were used to engineer
the MALDI-TOF MS database (Table 1). These strains were
obtained from three different sources. Eight strains were pur-
chased from the collections of BCCM-IHEM (Brussels, Bel-
gium), 12 from CBS (Centraalbureau voor Schimmelcultures,
Utrecht, The Netherlands) and eight from collections of clini-
cal isolates, previously well characterized by MLS. The tested
strains used to validate the databases were 124 clinical and 16
environmental fresh isolates of Aspergillus (see Supporting
Information). The clinical isolates were mainly recovered from
respiratory specimens (sputum and bronchoalveolar lavage)
and from nail and skin biopsy specimens. The environmental
isolates were from the air of our hospital. Clinical and environ-
mental isolates were identified by morphological observation,
and exact species were determined with a molecular method
based on MLS, using b-tubulin and/or calmodulin genes as pre-
viously described [3] (see Supporting Information). All of the
strains used in the study were stored at )80C in trypticase
soy broth supplemented with 15% glycerol.
MALDI-TOF MS
The strains were grown at 30C on Sabouraud dextrose
agar with chloramphenicol and gentamicin (BioRad, Marnes-
la-Coquette, France) and checked daily for maturation (suffi-
cient sporulation and mycelium development). Superficial
material, a mixture of spores, conidiophores and mycelium,
was collected gently at the surface of the colony, and mixed
in 1 lL of pure water previously deposited on a target plate
(Bruker Daltonics, Bremen, Germany). This mixture was
TABLE 1. Reference strains used to establish the matrix-
assisted laser desorption ionization time-of-flight mass spec-
trometry Aspergillus database
Section (n) Species Reference strain
Fumigati (11) Aspergillus fumigatus IHEM 1246
Aspergillus lentulus CBS 116879
Neosartorya pseudofischeri CBS 208.92
Neosartorya fischeri IHEM 660
Aspergillus fumigatiaffinis CBS 117194
Aspergillus fumisynnematus CNM-CM-4063
Aspergillus viridinutans CBS 127.56
Neosartorya udagawae CBS 114217
Neosartorya hiratsukae CBS 109356
Neosartorya spinosa CBS 483.65
Neosartorya fennelliae CBS 598.74
Flavi (5) Aspergillus flavus IHEM 306
Aspergillus oryzae CBS 115.33
Aspergillus tamarii FLA 17a
Petromyces alliaceus CBS 536.65
Aspergillus parvisclerotigenus FLA 30a
Terrei (1) Aspergillus terreus IHEM 5857
Nigri (3) Aspergillus niger IHEM 2864
Aspergillus tubengensis NIG 11a
Aspergillus foetidus NIG 15a
Nidulantes (4) Emericella nidulans IHEM 3665
Emericella quadrilineata CBS 426.77
Aspergillus sydowii IHEM 566
Aspergillus versicolor IHEM 2983
Usti (3) Aspergillus calidoustus CBS 121601
Aspergillus pseudodeflectus UST 26a
Aspergillus insuetus UST1a
Circumdati (1) Aspergillus ochraceus CIR 1a
CBS, Centraalbureau voor Schimmelcultures, Utrecht, the Netherlands; CNM-
CM, Centro Nacional de Microbiologia, Servicio de Micologia, Madrid, Spain;
IHEM, BCCM-IHEM collection, Brussels, Belgium.
aReference spectra established with clinical isolates identified by multilocus
sequencing.
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allowed to dry at room temperature. One microlitre of
absolute ethanol was then added to each well, and the mix-
ture was allowed to dry. One microlitre of matrix solution
(2,5-dihydroxybenzoic acid, 80 mg/mL, 30% acetonitrile, 0.1%
trifluoroacetic acid) was then added and allowed to co-crys-
tallize with the sample. An internal control with Pseudomonas
aeruginosa allowed us to validate the calibration for each
experiment. Samples were processed in the MALDI-TOF MS
spectrometer (Microflex; Bruker Daltonics) with the flex
control software (Bruker Daltonics). Positive ions were
extracted with an accelerating voltage of 20 kV in linear
mode. The analysis was performed with the flex analysis soft-
ware. The presence and absence of peaks were considered
to be fingerprints for a particular isolate. The profiles were
analysed and compared by use of Andromas software
(Andromas, Paris, France). Numerical data obtained from
the spectrometer acquisition software (peak value and rela-
tive intensity for each peak) were sent to the Andromas
software [24,28].
Results
Reference database construction
For each of the 28 reference strains, the MALDI-TOF MS
profile obtained from ten different runs was analysed. As
some differences were observed between the spectra from
young and mature colonies within a same species, two differ-
ent reference spectra were created for each reference
strain: one from young colonies (<2 days of sporulation) and
the other from mature colonies (between 4 and 10 days of
sporulation). Fig. 1 presents a selection of the specific spec-
tral fingerprints of young and mature colonies for three spe-
cies. The standard deviation for each conserved peak did not
exceed 10 m/z. The spectral fingerprints were specific for
each selected reference strain.
Validation of the database
We next aimed at determining whether the above database
could be used for identification of Aspergillus species. The
database was blindly tested with the set of 124 fresh clinical
and 16 environmental Aspergillus isolates.
The Andromas software identified the number of com-
mon peaks between the spectra of the tested isolate and
the species-specific fingerprints of the reference strains in
the database (i.e. Aspergilli database). For each isolate, all
peaks with an intensity >0.01 were retained and were com-
pared with that of the species-specific fingerprints of each
reference strain, as described above, taking into account
possible variations of ±10 m/z. Then, the percentage of
common peaks was obtained (100 · number of common
peaks between the tested isolate and the peaks of the
FIG. 1. Representation of the specific spectral
fingerprints of young and mature colonies for
three selected species.
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species-specific spectral fingerprint/total number of peaks
specific for the species-specific spectral fingerprint). Only
the first and second best matches were retained. Accept-
able identification of a tested strain corresponds to the spe-
cies having ‡66% of common peaks with the reference
strains in the database. A difference of at least 10%
between the first and the second match was required.
When the identification was not acceptable (i.e. <66% of
common peaks with reference strain or <10% of difference
between first and second matches), a second run was per-
formed and analysed in a similar manner.
With our database, 127 isolates were identified after a
single run, 11 were identified after two runs, and two could
not be identified. The results of MALDI-TOF MS identifica-
tion are presented for each section in Table 2. Identification
was correct for 138 of 140 (98.6%) isolates according to
our identification strategy. Two isolates for which MALDI-
TOF MS failed to give a spectrum were finally identified as
A. fumigatus by MLS (GenBank accession number
AY048754), whereas conventional morphological criteria did
not allow accurate identification, owing to the absence of
conidiogenesis for one and of atypical sporulation for
the other. No isolate was misidentified, leading to 100%
specificity.
Discussion
We have developed and validated a MALDI-TOF database
that allows precise identification of an extensive number of
Aspergillus species currently isolated in clinical settings, includ-
ing both common and recently described unusual species.
This identification procedure can be performed from
single colonies on Sabouraud dextrose agar whenever the
microbiologist suspects an Aspergillus mould from the pres-
ence of a characteristic conidial head by morphological
observation. We have developed a very simple and fast
experimental protocol that involves depositing the superficial
material collected from the surface of the mould colonies
directly onto the MALDI-TOF MS target plate without sub-
culture or colony preparation. Indeed, this avoids many labo-
rious sample preparation steps that are currently used to
pre-extract proteins, such as washings before using both eth-
anol and acid solution, or multiple centrifugations.
Because growth of the various Aspergillus species is neither
uniform nor equivalent in terms of sporulation, we have
developed a database that includes the species-specific spec-
tral fingerprints from young and mature colonies for all spe-
cies. Consequently, identification can be performed
regardless of the maturity of the tested isolate, thus making
MALDI-TOF MS a robust method for Aspergillus species iden-
tification. Our procedure allowed identification in <10 min
and at very low cost. MALDI-TOF MS appears to be the first
automatic phenotypic method available for accurate identifi-
cation of the most important Aspergillus species. For daily
identification of Aspergillus species in clinical microbiology lab-
oratories, MALDI-TOF MS could be used as a first-line
approach to confirm morphological findings.
In our (Bougnoux M-E, Alanio A, Lacroix C, unpublished
data) experience, some clinical respiratory samples, especially
from cystic fibrosis patients, frequently yield colonies of
Aspergillus species with variable morphological macroscopic
aspects. This raises the question of the presence of a mix-
ture of different Aspegillus species or of variation in growth.
Because of the low costs and speed of MALDI-TOF MS,
which is much faster and cheaper to perform than alternative
techniques for Aspergillus identification, such as the micro-
sphere-based Luminex assay [27,29], it might be an appropri-
ate tool to screen multiple colonies from a single clinical
sample in order to confirm or rule out the presence of a
mixture of different Aspergillus species isolates.
As a large number of new species involved in IA have
been recently reported, Aspergillus species identification has
become a real challenge in clinical laboratories. Indeed, a
major shift has been observed in the recent epidemiology of
TABLE 2. Identification results for the 124 clinical and 16
environmental isolates of Aspergillus obtained by matrix-
assisted laser desorption ionization time-of-flight mass spec-
trometry
Section Species
No. of
isolates
tested
No. of
isolates
correctly
identifieda
% of isolates
correctly
identifiedb
Fumigati Aspergillus fumigatus 50 48 96
Aspergillus lentulus 7 7 100
Neosartorya pseudofischeri 5 5 100
Neosartorya fischeri 1 1 –
Aspergillus fumigatiaffinis 2 2 –
Aspergillus fumisynnematus 1 1 –
Aspergillus viridinutans 2 2 –
Neosartorya udagawae 1 1 –
Neosartorya hiratsukae 2 2 –
Flavi Aspergillus flavus 13 13 100
Aspergillus tamarii 2 2 –
Aspergillus parvisclerotigenus 1 1 –
Terrei Aspergillus terreus 8 8 100
Nigri Aspergillus niger 9 9 100
Aspergillus tubengensis 1 1 –
Aspergillus foetidus 2 2 –
Nidulantes Emericella nidulans 4 4 –
Emericella quadrilineata 1 1 –
Aspergillus sydowii 7 7 100
Aspergillus versicolor 3 3 –
Usti Aspergillus calidoustus 14 14 100
Aspergillus pseudodeflectus 1 1 –
Aspergillus insuetus 1 1 –
Circumdati Aspergillus ochraceus 2 2 –
aIn comparison with identification obtained by partial gene sequence-based
method.
bCalculated only when the number of isolates was at least five.
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the species responsible for IA. Two distinct phenomena have
been observed. First, recent studies have documented cases
of IA caused by new Aspergillus species, such as N. fischeri
[14], N. pseudofischeri [15], N. hiratsukae [16], A. calidoustus
[19] and A. niveus [20]. These species, usually found in the
environment (i.e. soil, food and air), had not been identified
previously as potential pathogens in susceptible hosts (i.e.
immunocompromised patients in a haematological setting).
Second, new clinical species, previously unrecognized by phe-
notypic means, have been identified when collections of
Aspergillus strains isolated from IA cases have been with the
MLS method. These include species encompassing from same
section, such as Aspergillus species from sections Usti, Fumigati
or Nidulantes [10,17,30]. Indeed, these species display very
close morphological features. For instance, among 36 isolates
previously identified as A. fumigatus, it was recently found
that MLS clearly distinguished four isolates of N. uadagawae
from A. fumigatus sensu stricto [17]. Moreover, some of
these new species seem to be responsible for a form of
aspergillosis distinct from typical IA, as the clinical picture
displays either chronic or refractory aspects [17]. These
studies have stressed the fact that IA caused by unusual
Aspergillus species may account for a significant proportion of
aspergillosis cases, and highlighted the limitations of pheno-
typic methods for species identification within the Aspergillus
sections when different antifungal profiles have been
reported. Thus, different species from the same section have
been shown to display different antifungal susceptibility pat-
terns in vitro [11,30], proving that Aspergillus identification at
the species level might have clinical consequences in terms
of primary antifungal therapy. Indeed, recent guidelines rec-
ommend Aspergillus identification at the species level, to
enable adaptation of the antifungal treatment for the Aspergil-
lus species involved [2,21].
Our database includes fingerprints of the more relevant
species of Aspergillus involved in these cases of IA. The
panel of reference strains included in our study was con-
cordant with the distribution of Aspergillus species isolated
from patients. In addition, we have also studied and
included the recently described species, which cannot be
identified with traditional phenotypic approaches (non-A.
fumigatus species from the section Fumigati, Emericella
quadrilineata from the section Nidulantes, and A. insuetus or
Aspergillus pseudodeflectus from the section Usti) [8,10,30].
Our database cannot be exhaustive, because of the extre-
mely large number of Aspergillus species (more than 250).
However, the database will be rapidly updated when new
species involved in human pathology are described. Also,
our protocol does not yield identification for atypical
isolates of Aspergillus, such as sterile isolates. Indeed, in such
instances, the MLS strategy will remain the method of
choice for identification.
We believe that MALDI-TOF MS technology provides a
real opportunity to improve our knowledge of the epidemi-
ology of medically relevant Aspergillus species, by providing
fast and accurate identification of Aspergillus species isolated
in clinical practice. It should be useful in enabling the early
adaptation of antifungal therapy, in order to avoid microbio-
logical therapeutic failure when species with natural resis-
tance to some antifungal drugs are identified.
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